<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00944463</url>
  </required_header>
  <id_info>
    <org_study_id>2008-07-065</org_study_id>
    <nct_id>NCT00944463</nct_id>
  </id_info>
  <brief_title>Trial of Simvastatin and Gemcitabine in Pancreatic Cancer Patients</brief_title>
  <official_title>Randomized Double-blinded, Placebo-controlled Phase II Trial of Simvastatin and Gemcitabine in Advanced Pancreatic Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether simvastatin is effective in the treatment
      of advanced pancreatic cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine
      in advanced pancreatic cancer patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2008</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Every 2 cycles until progression</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profiles of gemcitabine/simvastatin</measure>
    <time_frame>Every cycle until progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Every 2 cycles until progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Every 2 cycles until progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Every 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlative analyses</measure>
    <time_frame>after completion of accrual</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine+simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine and simvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine+Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Gemcitabine plus Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine+simvastatin</intervention_name>
    <description>Gemcitabine and simvastatin</description>
    <arm_group_label>Gemcitabine+simvastatin</arm_group_label>
    <other_name>Gemcitabine and simvastatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine+Placebo</intervention_name>
    <description>Gemcitabine plus Placebo</description>
    <arm_group_label>Gemcitabine+Placebo</arm_group_label>
    <other_name>Gemcitabine plus Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 18 years

          2. Histologically or cytologically confirmed, metastatic or unresectable pancreatic
             adenocarcinoma (if repeated biopsy (&gt;3) fails or if biopsy is not feasible, the
             inclusion of the patient will be determined by the central PI)

          3. ECOG performance status of 0~2

          4. no radiotherapy within 1 month of the study entry

          5. measurable or evaluable lesion according to RECIST criteria

          6. no prior history of chemotherapy for pancreatic cancer (gemcitabine-based adjuvant
             chemotherapy ≥ 12 months from the study entry will be allowed)

          7. adequate marrow, hepatic, renal and cardiac functions (absolute neutrophil count ≥ 1.5
             x 109/L; platelet count ≥ 75 x 109/L, serum creatinine ≤ 1.5 x ULN), serum aspartate
             aminotransferase/alanine aminotransferase ≤ 5 x ULN or ≤ 10 x ULN if liver
             abnormalities are due to underlying malignancy; total bilirubin ≤ 2.0 x ULN

          8. written informed consent must be provided

        Exclusion Criteria:

          1. severe co-morbid illness and/or active infections

          2. pregnant or lactating women

          3. active CNS metastases not controllable with radiotherapy or corticosteroids A.patients
             with symptoms suggestive of CNS metastases must undergo radiologic evaluation to rule
             out metastases B.patients with known, asymptomatic CNS lesions are permitted

          4. known history of hypersensitivity to study drugs

          5. patients who are currently on statin therapy or has taken statin as lipid lowering
             agents within 1 year of the study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young Suk Park, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center, Seoul, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2009</study_first_submitted>
  <study_first_submitted_qc>July 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2009</study_first_posted>
  <last_update_submitted>February 15, 2017</last_update_submitted>
  <last_update_submitted_qc>February 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Young Suk Park</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>advanced pancreatic cancer</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>simvastatin</keyword>
  <keyword>placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

